Summary
Doxorubicin Hydrochloride has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Multiple Myeloma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Multiple Myeloma. ClinicalTrials.gov lists 8 registered trials linking Doxorubicin Hydrochloride to Multiple Myeloma: 1 is active or not yet recruiting; 7 have completed. The most advanced is Phase 3 (NCT00002878). The largest enrolment is 72 participants (NCT00401804). Registration activity spans 1997 to 2017. No published literature item is linked to Doxorubicin Hydrochloride and Multiple Myeloma in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Multiple Myeloma ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Essentially zero; MGUS (precursor) progresses to myeloma in 1%/year; median survival without treatment <1 year once symptomatic.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 48.5 (trials 28.5, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 1 active / not yet recruiting, 7 completed, 0 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | CCND1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00002878 | Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma 1997 | completed | Phase 3 | — |
| NCT03004287 | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy 2017 | active, not recruiting | Phase 2 | 50 |
| NCT00008242 | Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma 2000 | completed | Phase 2 | — |
| NCT00148317 | Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma 2005 | completed | Phase 2 | 38 |
| NCT00006184 | Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma 2001 | completed | Phase 2 | 20 |
| NCT01849783 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma 2013 | completed | Phase 2 | 41 |
| NCT00401804 | Bortezomib-Dexamethasone-Doxorubicin-Study 2006 | completed | Phase 2 | 72 |
| NCT00135187 | Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma 2004 | completed | Not applicable | 30 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CCND1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Doxorubicin Hydrochloride approved for Multiple Myeloma?
Doxorubicin Hydrochloride has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Multiple Myeloma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Multiple Myeloma. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Doxorubicin Hydrochloride in clinical trials for Multiple Myeloma?
ClinicalTrials.gov lists 8 registered trials linking Doxorubicin Hydrochloride to Multiple Myeloma: 1 is active or not yet recruiting; 7 have completed. The most advanced is Phase 3 (NCT00002878). The largest enrolment is 72 participants (NCT00401804). Registration activity spans 1997 to 2017.
What does the evidence show for Doxorubicin Hydrochloride in Multiple Myeloma?
Doxorubicin Hydrochloride has 7 completed registered trials for Multiple Myeloma but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CCND1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.